Nabila Hassan Ahmed1, Ahmed Embaby2, Amira Elwan3, Essam Adel Abdelrahman2, Ahmed S Mohamed1
1Tropical Department, Faculty of Medicine, Zagazig University,
Egypt.
2Internal Medicine Department, Faculty of Medicine,
Zagazig University, Zagazig, Egypt.
3Clinical Oncology Department, Faculty of Medicine,
Zagazig University.
Corresponding author:
Dr. Nabila Hassan Ahmed.
Mail:nabilaahassanahmed@gmail.com.
Tel no: +201224892292.
DOI: 10.21608/ajgh.2022.177155.1021.
Abstract:
Background:
Direct Anti Hepatitis C Viral Agents (DAAs) were
introduced for Hepatitis C Virus (HCV) infection management, which resulted in
high sustained virological response (SVR) in many countries and a low failure
rate. However, hepatocellular carcinoma (HCC) post DAAs therapy is
controversial; few studies related aggressive pattern HCC
to DAAs. Therefore, we aimed to study the hepatocellular
carcinoma relation to direct anti-hepatitis C viral drugs.
Patients
and Methods: This observational case-control study included 67 adult Egyptian
HCC patients associated with HCV diagnosed at the Zagazig University Hospitals,
who were divided into two groups according to DAAs treatment.
Results:
HCC is more common in male patients (77.6%) of
all studied cases, and those are treated by DAAs (62.7%). The median age of HCC
post DAA was 63(48-83), while 58 (45-75) in HCC patients without DAA, with no
significant difference p= 0.053. HCC presented in the non-DAAs treated group,
mainly decompensating by hematemesis (HM) (32%). While in the post-DAAs group,
HCC was significantly diagnosed mainly by abdominal pain at 31%. There is no
significant difference as regards the liver status with frequent liver
cirrhosis in both groups, 14(56%) and 32(76.2%). Liver cirrhosis (p-value 0.04)
and advanced Child-Pugh classification (p-value 0.009) are predictors of
DAAs-related HCC.
Conclusion: DAAs therapy of HCV added no additional risk for hepatocellular
carcinoma.
Comments